Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock - Wikidata - awgldk - TriplyDB

Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock

Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock

http://www.wikidata.org/entity/Q24198059

about

Intravenous immunoglobulin for suspected or proven infection in neonates The Production Processes and Biological Effects of Intravenous Immunoglobulin Natural IgM: beneficial autoantibodies for the control of inflammatory and autoimmune disease New aspects in the management of pneumonia Management and Novel Adjuncts of Necrotizing Soft Tissue Infections.The Combining Sites of Anti-lipid A Antibodies Reveal a Widely Utilized Motif Specific for Negatively Charged Groups Management of intra-abdominal infections: recommendations by the WSES 2016 consensus conference Intravenous immunoglobulin for severe sepsis and septic shock: clinical effectiveness, cost-effectiveness and value of a further randomised controlled trial.The Japanese guidelines for the management of sepsis.Allopurinol hypersensitivity syndrome in patients with hematological malignancies: characteristics and clinical outcomes.Gut Microbiota-Induced Immunoglobulin G Controls Systemic Infection by Symbiotic Bacteria and Pathogens The Effect of Intravenous Immunoglobulin Combined with Corticosteroid on the Progression of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Meta-Analysis.Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial.Association between cytokine response, the LRINEC score and outcome in patients with necrotising soft tissue infection: a multicentre, prospective study.Low-dose immunoglobulin G is not associated with mortality in patients with sepsis and septic shock.Dynamic interactions of Plasmodium spp. with vascular endothelium.Anti-inflammatory Properties of Antimicrobial Peptides and Peptidomimetics: LPS and LTA Neutralization.Commercial Intravenous Immunoglobulin (IVIg) Preparations Contain Functional Neutralizing Antibodies Against the Staphylococcus aureus Leukocidin LukAB (LukGH).IgM-enriched solution BT086 improves host defense capacity and energy store preservation in a rabbit model of endotoxemia.A critical role for ATF2 transcription factor in the regulation of E-selectin expression in response to non-endotoxin components of Neisseria meningitidis.The original sins of clinical trials with intravenous immunoglobulins in sepsis.The protective association of endogenous immunoglobulins against sepsis mortality is restricted to patients with moderate organ failure.Malaria-associated secondary haemophagocytic lymphohistiocytosis: Report of two cases & a review of literature.Use of intravenous immunoglobulin to treat sepsis in a general ICU.Treatment of Acute Kidney Injury Complicating Septic Shock with EMiC2 High-cutoff Hemofilter: Case Series.IgM Augments Complement Bactericidal Activity with Serum from a Patient with a Novel CD79a Mutation.The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016 (J-SSCG 2016).Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study).Septic shock from descending necrotizing mediastinitis - combined treatment with IgM-enriched immunoglobulin preparation and direct polymyxin B hemoperfusion: a case report.Intravenous immunoglobulin fails to improve ARDS in patients undergoing ECMO therapy.Igm-enriched polyclonal immunoglobulins in an experimental model of gram negative pneumonia developing septic shock.

P2860

Q24187127-C3262C49-D450-4ACE-A489-4245F73AC02B Q26752540-E87C3176-72C7-4764-9EB2-A2002274FA71 Q27021242-98479D8D-E7F9-40FE-B759-B8ADFD8E457A Q28080025-A962E3F3-B1A8-4ADB-B3D0-E5A166DC7F56 Q30234954-3760702B-4D40-4A23-A304-CE24E3151D41 Q30385146-4A60E0F5-73A3-4CFE-A0E6-4B8E280F07BA Q33640559-04961C12-4147-4377-8EB3-CF25BDF64AF5 Q34739999-128D6D54-64F0-4B94-B712-1837FB9113C1 Q35107094-C885F351-3993-4AC1-BE00-367A86F758E2 Q35834966-3B54F257-4EE8-405C-955D-18685952F23E Q35946361-58DF7D4D-EB65-48C8-AFAA-54E89DE0DAA8 Q36208161-031D7C7E-1F6C-4C17-AABD-7A4B2274520E Q36406243-5F8131C7-23BF-4FA8-89A1-01862A715AA4 Q37630684-ED73CF71-83F2-41F2-AA25-BBC672B393DF Q38682155-347E4DB8-1D67-4938-8E75-C20B29A03402 Q38689845-7B1321F0-9BD1-4600-AA30-D7E846BA72A8 Q39066110-67D29FA2-763B-42B4-818C-274590944C6A Q40065980-CBFEB57B-82CE-41D7-A217-96A26D73427F Q40336829-AC29F465-6A4A-4C95-82CF-E240BC757807 Q40759726-4E9F7DA5-1B0D-400C-9573-1A3242C7E8CE Q41325253-4423E895-6304-4773-AE2D-24983865E205 Q42290901-8752D073-769E-44C4-9848-E14DC44B02D8 Q42345273-1E911FFB-879E-487A-A300-C9F126C0B02F Q46079204-15239CED-160D-4D4A-A658-7901A2C0B433 Q47119189-4334DB06-384F-4730-829B-F10B361CE668 Q47656534-BC35368A-BA9A-4C05-8841-42540CF588FA Q50052469-DDA01224-549C-4BFF-93A2-3771C2EF5FD5 Q52597380-D9389FAF-9593-4D1B-803A-ACAEA5C8AD62 Q53705132-FB515136-6598-419F-916C-5F16ACC76B99 Q54263553-1B9237D4-286C-451D-9DD8-07FD838257A6 Q54886771-F12D4431-9CC8-461D-B20E-CD84D1E042F6

P2860

Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock

http://www.wikidata.org/entity/Q24198059

description

2013 nî lūn-bûn

@nan

2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock

@ast

Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock

@en

Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock

@en-gb

Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock

@nl

type

label

Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock

@ast

Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock

@en

Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock

@en-gb

Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock

@nl

prefLabel

Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock

@ast

Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock

@en

Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock

@en-gb

Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock

@nl

P1433

Q24198059-59BCD037-43AA-4FB9-BD4A-59ACB87CA58A

P1476

Q24198059-EC4A786F-9AF5-41C8-8F55-1509ADBD52CC

P2093

Q24198059-41CD26BD-CCE5-4CDA-8F69-A6B0204514C2

Q24198059-820178DE-36AD-4D03-B536-211D5B228E0C

Q24198059-AA5A08C8-B56D-4E6E-9131-D1633EE64EDC

P2860

Q24198059-1736B4C1-321B-481D-BA91-F73C7D0B9B2E

Q24198059-179AFE9E-B6D6-40CD-9EE6-DAEE20E75AE7

Q24198059-192A4567-1B3B-46CA-BE33-86F0CA5328FF

Q24198059-23A41AF6-6D49-4CE5-9053-11DAB6C87E8C

Q24198059-2CEDDBD4-1AE6-4D2B-9D5D-DB4553CDCA19

Q24198059-2F66CAC0-8F23-4436-A120-4D27AA3C5770

Q24198059-3C423D52-65AB-4C9C-A2BD-8114E0844B06

Q24198059-3C4D4FA8-F180-404A-A6A5-12EB371AC775

Q24198059-3F737BCA-5FB2-43E6-A0E7-02FC6A35AFC3

Q24198059-3FECC8FF-2B2F-42E6-8356-7B5A2A0AEFBC

P304

Q24198059-1F6E9E5C-64AA-4C5A-A483-A75D79EB53B3

P31

Q24198059-16F0E11A-43A8-48BD-8DD3-C174B1F62CE4

P3181

Q24198059-E93D27B1-DA2A-428A-B750-8DA31945E3BF

P356

Q24198059-9E08D783-AF8A-460B-967D-F105C597E21C

P433

Q24198059-A76E566E-A0FD-4C8B-81BF-F8DAFC89659A

P50

Q24198059-7BFEBA88-1F70-47CC-AEC1-00E57322C804

P577

Q24198059-B6569D6A-5D2A-4EF0-AAF4-1B265C96FD08

P698

Q24198059-23D14727-2339-4C67-85F6-D7420575B9E6

P921

Q24198059-C7E41FC5-4495-4A82-A34C-550C608943AE

P932

Q24198059-8438D82D-7DAB-41D5-867A-9EC18268C54B

P3181

P356

14651858.CD001090.PUB2

P1433

Cochrane Database of Systematic Reviews

P1476

Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock

@en

P2093

Jacinto Blas Mantaring

http://www.w3.org/2001/XMLSchema#string

Leonila F Dans

http://www.w3.org/2001/XMLSchema#string

Marissa M Alejandria

http://www.w3.org/2001/XMLSchema#string

P2860

Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine

Intravenous immunoglobulin for suspected or proven infection in neonates

Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008

The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis: another point of view

The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis [ISRCTN28863830].

An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of inf

Early goal-directed therapy in the treatment of severe sepsis and septic shock

Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012

Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels

2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference

P304

CD001090

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3217364

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/14651858.CD001090.PUB2

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P50

Mary Ann Lansang

P577

2013-09-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24043371

http://www.w3.org/2001/XMLSchema#string

P921

P932

6516813

http://www.w3.org/2001/XMLSchema#string